⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
globenewswire.com
VNDA
GRFS
BHC
RDHL
MRK
TEVA
PFE
SNY
LLY
ABBV
AZN
CRCT
SPRO
CRNX
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
prnewswire.com
VNDA
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
prnewswire.com
VNDA
ANAB
Vendavo Named a Leader in the Gartner® Magic Quadrant™ for B2B Pricing & Rebate Optimization Software
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
prnewswire.com
VNDA
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Vanda Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm
globenewswire.com
VNDA
Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress
businesswire.com
VNDA